RxDoctor Payments Data

Catherine Dillane

Cardiovascular Disease · King Of Prussia, PANPI 1083029888

Payments from drug & device makers

$1,776in general payments, 2019–2025

Across 123 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$564
  • Boston Scientific$284
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$209
  • Impulse Dynamics (USA) Inc.$83
  • Esperion Therapeutics, Inc.$70
  • Johnson & Johnson$68
  • plus $499 from 13 others

What the payments were for

  • Food & beverage$1,76299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,776 in reported general payments places this provider in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$190,200
Medicare patients
636
Services billed
2,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$106,601
EntrestoSacubitril/Valsartan43$53,755
JardianceEmpagliflozin18$22,391
XareltoRivaroxaban18$22,135
FarxigaDapagliflozin Propanediol11$16,776
Repatha SyringeEvolocumab11$15,188
Repatha SureclickEvolocumab12$14,270
Amlodipine-AtorvastatinAmlodipine/Atorvastatin49$11,426
Ezetimibe148$6,074
Rosuvastatin Calcium246$4,939
Metoprolol Succinate206$3,507
Atorvastatin Calcium232$3,404
Ranolazine ErRanolazine34$3,026
Valsartan84$2,848
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$2,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$106,60185 claims
NovartisEntresto$564$53,75543 claims
Boehringer IngelheimJardiance$16$22,39118 claims
Johnson & JohnsonXarelto$68$22,13518 claims
AstraZenecaFarxiga$51$16,77611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in King Of Prussia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →